Answers are grounded in this paper and cite their sources.
Omalizumab diminished clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of approved doses of H-antihistamines. (Funded by Genentech and Novartis Pharma; ClinicalTrials.gov number, NCT01292473.).
No takes yet. Share an insight, caveat, or question.
Maurer et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: